ImmunityBio (IBRX) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Krystal Biotech (KRYS) over the past year, gaining 290.0% versus a gain of 77.3%. Over five years, KRYS leads with a +566.2% price change compared with +4.8% for IBRX. ImmunityBio is the larger company by market cap ($10.33 billion vs $9.61 billion), about 1.1 times the size.
Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | KRYS |
|---|---|---|
| Share price | $9.75 | $324.57 |
| Market cap | $10.33B | $9.61B |
| 1-day change | +0.62% | -0.69% |
| YTD return | +392.42% | +31.65% |
| 1-year return | +290.00% | +77.34% |
| 5-year return | +4.84% | +566.19% |
| P/E ratio (TTM) | — | 40.98 |
| Forward P/E | — | 34.83 |
| EPS (TTM) | $-0.97 | $7.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $389.13M |
| Revenue growth (YoY) | +668.31% | +33.94% |
| Net income (latest FY) | $-351.40M | $204.83M |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | 41.45% |
| Net margin | -310.18% | 52.64% |
| 52-week high | $12.43 | $382.54 |
| 52-week low | $1.95 | $179.19 |
| Distance from 52-week high | -21.56% | -15.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +30.77% | +20.81% |
| Average volume | 10.27M | 381.19K |
| Shares outstanding | 1.06B | 29.60M |
| Employees | 684 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed KRYS by 212.7 percentage points over the past year.
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +33.94%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
IBRX vs KRYS FAQ
Which is bigger, ImmunityBio or Krystal Biotech?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.33B compared with $9.61B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, IBRX or KRYS?
IBRX returned +290.00% over the past 12 months, compared with +77.34% for KRYS (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.